Recent antimalarial drug discovery has been a race to produce new medicines that
overcome emerging drug resistance, whilst considering safety and improving dosing …

Aminoacyl-tRNA synthetases (ARSs) are essential enzymes for protein synthesis with
evolutionarily conserved enzymatic mechanisms. Despite their similarity across organisms …

Antimalarial drugs have thus far been chiefly derived from two sources—natural products
and synthetic drug-like compounds. Here we investigate whether antimalarial agents with …

Aminoacyl-tRNA synthetases (ARSs) are universal enzymes that catalyze the attachment of
amino acids to the 3′ ends of their cognate tRNAs. The resulting aminoacylated tRNAs are …

Infections caused by malaria parasites place an enormous burden on the world's poorest
communities. Breakthrough drugs with novel mechanisms of action are urgently needed. As …

Aminoacyl-tRNA synthetases (aaRSs) catalyze the esterification of tRNA with a cognate
amino acid and are essential enzymes in all three kingdoms of life. Due to their important …

Development of antimalarial compounds into clinical candidates remains costly and arduous
without detailed knowledge of the target. As resistance increases and treatment options at …

Covering: up to the second quarter of 2020 Threat or treat? While pathogenic bacteria pose
significant threats, they also represent a huge reservoir of potential pharmaceuticals to treat …

Although many new anti-infectives have been discovered and developed solely using
phenotypic cellular screening and assay optimization, most researchers recognize that …

Mechanistic target of rapamycin complex 1 (mTORC1) controls cell growth and proliferation
by sensing fluctuations in environmental cues such as nutrients, growth factors, and energy …